Heart scan study of a diabetes drug for non-diabetic heart attack patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a heart attack or unstable angina and had a procedure to open blocked arteries (PCI).
- You have multiple blocked heart arteries, and at least one blocked artery was not treated with a stent.
- You do not have diabetes or chronic heart failure.
- You have not taken an SGLT2 inhibitor (like empagliflozin or dapagliflozin) in the past 4 weeks.
- You do not have severe liver or kidney problems, low blood pressure, or a history of frequent urinary or genital infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
Hear when a new SGLT2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.